# Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

> **NCT02044627** · PHASE1 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** [14C-ETC-1002]

## Key facts

- **NCT ID:** NCT02044627
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044627, "Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02044627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*